AC
NBSE

Armistice Capital’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Armistice Capital’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-166,174
Closed -$311K – 292
2023
Q2 		$311K Buy
+166,174
New +$547K ﹤0.01% 171

Other funds holding NBSE

GC
Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
CMU
Carnegie Mellon University Pittsburgh, Pennsylvania $78.9M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KAS
Kestra Advisory Services Austin, Texas $31B AUM 28.39% 1-Year Est. Return
JAMONY
Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.37B AUM 71.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Armistice Capital's NBSE Position: Q3 2023 in Review

Armistice Capital sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q3 2023, closing a stake of 166,174 shares — an estimated $311K sold.

Armistice Capital first reported a position in NBSE in Q2 2023 and held it in 1 quarter. The position peaked at $311K in Q2 2023. 21 funds tracked by Wall St. Rank hold NBSE as of Q3 2023.

  • Armistice Capital reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Armistice Capital sold 166,174 NeuBase Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $311K.
  • Armistice Capital first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q2 2023 and held it in 1 quarter.
  • Armistice Capital's NeuBase Therapeutics, Inc. Common Stock position peaked at $311K in Q2 2023.
  • 21 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Armistice Capital's 13F filing for Q3 2023, filed 14 Nov 2023.